These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28338626)

  • 1. In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01.
    Hirasawa M; Hagihara K; Abe K; Ando O; Hirayama N
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex.
    Hirasawa M; Hagihara K; Abe K; Ando O; Hirayama N
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29867033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01.
    Hirasawa M; Hagihara K; Okudaira N; Izumi T
    PLoS One; 2015; 10(6):e0130928. PubMed ID: 26098642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity.
    Lundgren H; Martinsson K; Cederbrant K; Jirholt J; Mucs D; Madeyski-Bengtson K; Havarinasab S; Hultman P
    PLoS One; 2017; 12(9):e0184744. PubMed ID: 28934241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based selection of human metabolite binding P4 pocket of DRB1*15:01 and DRB1*15:03, with implications for multiple sclerosis.
    Misra MK; Damotte V; Hollenbach JA
    Genes Immun; 2019 Jan; 20(1):46-55. PubMed ID: 29362509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino acid variation within the binding pocket 7 and 9 of HLA-DRB1 molecules are associated with primary Sjögren's syndrome.
    Huang R; Yin J; Chen Y; Deng F; Chen J; Gao X; Liu Z; Yu X; Zheng J
    J Autoimmun; 2015 Feb; 57():53-9. PubMed ID: 25582848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic peptide molecular recognition by the DRB1-DQB1 haplotype modulates multiple sclerosis susceptibility.
    Kumar A; Melis P; Genna V; Cocco E; Marrosu MG; Pieroni E
    Mol Biosyst; 2014 Aug; 10(8):2043-54. PubMed ID: 24853027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homology modelling of frequent HLA class-II alleles: A perspective to improve prediction of HLA binding peptide and understand the HLA associated disease susceptibility.
    Kashyap M; Farooq U; Jaiswal V
    Infect Genet Evol; 2016 Oct; 44():234-244. PubMed ID: 27421208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells.
    Darnell M; Karlsson JE; Owen A; Hidalgo IJ; Li J; Zhang W; Andersson TB
    Drug Metab Dispos; 2010 Mar; 38(3):491-7. PubMed ID: 20023051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran.
    Kenne K; Skanberg I; Glinghammar B; Berson A; Pessayre D; Flinois JP; Beaune P; Edebert I; Pohl CD; Carlsson S; Andersson TB
    Toxicol In Vitro; 2008 Apr; 22(3):730-46. PubMed ID: 18191936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity.
    Hirayama N
    Drug Metab Pharmacokinet; 2017 Feb; 32(1):31-39. PubMed ID: 27964952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding Patterns Associated Aß-HSP60 p458 Conjugate to HLA-DR-DRB Allele of Human in Alzheimer's Disease: An In Silico Approach.
    Padmadas N; Panda PK; Durairaj S
    Interdiscip Sci; 2018 Mar; 10(1):93-104. PubMed ID: 27106586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
    Petros Z; Makonnen E; Aklillu E
    OMICS; 2017 Mar; 21(3):123-131. PubMed ID: 28253087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of HLA-DR and Topoisomerase I Epitope Modulated Genetic Risk for Systemic Sclerosis.
    Kongkaew S; Rungrotmongkol T; Punwong C; Noguchi H; Takeuchi F; Kungwan N; Wolschann P; Hannongbua S
    Sci Rep; 2019 Jan; 9(1):745. PubMed ID: 30679605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
    Sjödin E; Fritsch H; Eriksson UG; Logren U; Nordgren A; Forsell P; Knutson L; Lennernäs H
    Drug Metab Dispos; 2008 Aug; 36(8):1519-28. PubMed ID: 18458048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease.
    Inaba H; Martin W; De Groot AS; Qin S; De Groot LJ
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2286-94. PubMed ID: 16595602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
    Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
    Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.